Shares of Suven Life Sciences were up 3.7% at Rs 58.60 after hitting a 52-week on receipt of two product patents one each from US and Japan corresponding to its New Chemical Entities (NCEs).
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," says Venkat Jasti, CEO of Suven Life Sciences.
The NCEs are for the treatment of disorders assosciated with neurodegenerative diseases and these Patents are valid through 2026 and 2028, respectively, the company said in a release.
With these new patents, Suven has a total of fifteen granted patents from USA and seven granted patents from Japan, the release said.
Over 1.3 million shares were traded so far on both the stock exchanges.
